Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors

Bone Marrow Transplantation

Volumn 48, Issue 7, 2013, Pages 922-925

  Schmitt, M ^a,b   Xu, X ^a   Hilgendorf, I ^a   Schneider, C ^a   Borchert, K ^a   Glaser D ^a   Freund, M ^a   Schmitt, A ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

biosimilars; G CSF; SCT; stem cell donors; stem cell mobilization

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; CD3+ T LYMPHOCYTE; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENGRAFTMENT; HEMATOPOIESIS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; COHORT STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; RECOMBINANT PROTEINS; UNRELATED DONORS;

EID: 84880228272     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.270     Document Type: Article

References (21)

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006; 42: 2433-2453.
2. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. American Society of Clinical Oncology. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
3. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J 2008; 3: 90-97.
4. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011; 86: 277-288.
5. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012; 7(Suppl 1): 29-34.
6. Schofield I. EC defends biosimilar safety. Scrip 2008; 1: 3358.
7. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19: 411-419.
8. European Medicines Agency. Assessment Report for Ratiograstim. Nonproprietary Name: filgrastim (EMEA/H/C/825)Available from http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Public-assessment- report/human/000825/ WC500047793.pdf.
9. Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie 2009; 32: 599-604.
10. Sheridan B, Fox A. Feature on biopharmaceuticals: views from the pharmaceutical industry - significant questions relating to efficacy and immunogenicity will remain at approval. Eur J Hosp Pharmacy Practice 2007; 13: 70-73.
11. European Group for Blood and Marrow Transplantation (EBMT). Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donorsAvailable from http://www.worldmarrow. org/fileadmin/Committees/CLWG/Biosimilars/Biosimilars- 9Jan09.pdf.
12. del Giglio A, Eniu A, Ganae-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to NeupogenTM in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle I in breast cancer patients receiving decetaxel/doxorubicin chemotherapy. BCM Cancer 2008; 8: 332-339.
13. Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharm Therap 2009; 47: 275-282.
14. Lubenau H, Bias P, Maly A-K, Siegler KE, Mehltretter K. Pharmakokinetic and pharmacodynamic profile of new biosimilar Filgrastim XM02 equivant to market Filgrastim Neupogen. Biodrugs 2009; 23: 43-51.
15. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009; 4: 736-740.
16. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte conoly-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009; 50: 374-379.
17. Schmitt M, Diestel L, Xu X, Borchert K, Gläser D, Hilgendorf I et al. Application of the G-CSF biosimilar Ratiograstims for the mobilisation of peripheral stem cells in healthy donors. Onkologie 2011; 34(Suppl 6): P926.
18. Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. Eur J Haematol 2011; 88: 154-158.
19. Laszlo D, Andreola G, Babic A, Rabascio C, Montinaro A, Morabito L et al. Martinelli Plerixafor in combination with originator or biosimilar XM02-G-CSF as first-line peripheral blood stem cell mobilisation strategy in patients with lymphomas and multiple myeloma candidate to ASCT: a single-centre experience. Bone Marrow Transplant 2012; 47: P709.
20. Sever M, Domanovic D, Vrtovec B, Lezaic L, Pretnar J, Poglajen G et al. Mobilisation of heart failure patients using biosimilar granulocyte colony stimulating factor (TevaGrastim) for autologous CD34+ cells preparation and application into the heart. Bone Marrow Transplant 2012; 47: P726.
21. Publicover A, Richardson DS, Hill K, Hurlock C, Casey P, Newman J et al. Use of biosimilar G-CSF for peripheral blood progenitor cell mobilisation prior to autologous stem cell transplantation: a single-centre experience. Bone Marrow Transplant 2010; 45: P595.